Atlas Genetics raises $20M in series C round

Diagnostics company Atlas Genetics Ltd. (Trowbridge, U.K.) raised $20 million in a series C round from new investor RMI Partners, a subsidiary of Rusnano, and existing investors Novartis Venture Funds; Consort Medical plc; Johnson & Johnson Development Corp. (JJDC), the venture arm of Johnson & Johnson (NYSE:JNJ); LSP; BB Biotech Ventures; and South West Ventures Fund.

The company expects to launch its Atlas io system in Europe this year as a diagnostic for chlamydia. The point-of-care diagnostic detects nucleic acids present in a variety of bacterial infections including chlamydia and methicillin-resistant Staphylococcus aureus (MRSA) infection. The company is planning U.S. clinical trials of the system. ...